Cancer is not classified as a parasite in any formal biological taxonomy, but the comparison has moved well beyond metaphor in recent years. Researchers studying how tumors hijack host resources, dodge immune defenses, and remodel surrounding tissue have found that cancer cells deploy strategies strikingly similar to those of parasitic organisms, particularly parasitic worms. A 2025 review in The EMBO Journal put it bluntly: cancer cells “strategically exploit their host with parasitic precision,” mirroring the survival tactics of helminths so closely that the resemblance likely reflects shared evolutionary origins rather than coincidence.1PubMed Central. Cancer in disguise: a parasite within The question of whether cancer “is” a parasite turns out to be less about semantics and more about what the parasitic lens reveals about how tumors work and how we might treat them.
Why Scientists Keep Comparing Cancer to a Parasite
The comparison is old. As far back as the 1980s, biochemists noticed that cancer cells and parasites use similar molecular mechanisms to survive inside a host. Cancer cells, one early analysis argued, behave like normal cells that have lost their growth controls and “acquired parasitic features.”2Trends in Biochemical Sciences. Cancer cells and parasites. The homology of similarities What has changed since then is that the comparison now has molecular specifics behind it, not just a surface-level resemblance.
A parasite, in the broadest ecological sense, is an organism that lives in or on a host, draws nutrients from that host, and causes the host harm. A tumor does all three. It roots itself in host tissue, diverts blood supply and metabolic fuel to feed its own growth, and damages the host progressively. The sticking point is the word “organism.” In conventional biology, a parasite is a distinct species with its own genome and evolutionary lineage. A standard human tumor is made up of the patient’s own cells gone rogue. It shares the host’s genome, with mutations layered on top. That distinction matters taxonomically, but it blurs in fascinating ways when you look at how the tumor actually operates day to day.
Feeding Off the Host
One of the most compelling parallels is metabolic. Tumors do not just passively benefit from the body’s blood supply. They actively coerce surrounding cells into producing fuel for them. Researchers have described this as a “host-parasite relationship” in which the tumor reprograms the stromal cells around it, particularly fibroblasts, into what amounts to a feeding apparatus.3PubMed. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
Here is how it works in practice. The cancer cells send signals to neighboring fibroblasts, pushing them into a stressed metabolic state in which they break down their own components and release energy-rich molecules like lactate and pyruvate. The cancer cells then absorb those molecules and burn them efficiently in their own mitochondria to power rapid growth.4PubMed Central. Energy transfer in “parasitic” cancer metabolism: mitochondria are the powerhouse and Achilles’ heel of tumor cells In essence, the tumor “corrupts” normal tissue and turns it into a factory that exists to serve the tumor’s energy needs. That dynamic is remarkably similar to how a parasitic worm manipulates its host’s biology to extract nutrition.
Tumors also hijack the host’s vascular system. Solid tumors recruit blood vessels from surrounding healthy tissue, co-opt existing vessels, and stimulate the growth of new ones through a process called angiogenesis. The result is a tumor-specific blood supply network that looks and functions very differently from the orderly vascular system of healthy tissue.5PubMed Central. Integrative models of vascular remodeling during tumor growth Again, the analogy to a parasite redirecting host resources to sustain itself is hard to avoid.
Dodging the Immune System the Same Way Worms Do
The overlap between cancer and parasites is perhaps most striking in how they handle the host’s immune system. Both need to avoid being destroyed by immune cells, and both appear to use some of the same molecular tools to do it.
When researchers exposed human immune cells (monocytes) to cancer cell lines and then to live parasitic worm larvae, both exposures triggered remarkably similar changes. The monocytes upregulated surface molecules called PDL1 and PDL2, which are “off switches” that dampen the immune response. Both cancer cells and helminth parasites pushed monocytes toward a profile that suppresses inflammation rather than attacking the invader.6PubMed Central. Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: Insights into parallel mechanisms of immune evasion PDL1 has become a household name in cancer treatment because checkpoint immunotherapy drugs work by blocking exactly this “off switch.” The finding that parasitic worms flip the same switch suggests the tactic is ancient.
The broader picture, as the 2025 EMBO review argues, is that cancer cells have co-opted deeply conserved evolutionary strategies that parasites developed over millions of years: immune evasion, tissue remodeling, and the triggering of type-2 immune responses (the kind the body mounts against worms, as opposed to the type-1 responses aimed at bacteria and viruses).1PubMed Central. Cancer in disguise: a parasite within The implication is not that tumors “learned” these tricks from parasites but that both arrived at the same solutions because evading a mammalian immune system presents the same challenges whether you are a worm or a rogue cell.
Transmissible Cancers That Really Are Parasites
If the metabolic and immunological parallels are already strong, a small but extraordinary category of cancers collapses the gap entirely. Transmissible cancers are cancer cell lines that spread from one individual to another like an infectious agent. Once transferred, they grow in the new host, deriving nutrients from it and causing it harm. These cancers function, for all practical purposes, as parasitic organisms.
The best-studied example is canine transmissible venereal tumor, or CTVT. This cancer spreads between dogs during mating or other close physical contact through the transfer of living tumor cells. Genome sequencing revealed that every CTVT tumor worldwide traces back to a single dog that lived roughly 11,000 years ago. That original cell lineage has been passing from dog to dog across continents ever since, accumulating about 1.9 million mutations along the way while remaining remarkably stable as a clonal lineage.7PubMed Central. Transmissible dog cancer genome reveals the origin and history of an ancient cell lineage CTVT is effectively the longest-lived somatic cell lineage known. It has its own evolutionary trajectory, its own mutation history, and it persists by colonizing new hosts. By any ecological definition, it is a parasite.
Tasmanian devils face an even grimmer version. Devil facial tumor disease, or DFTD, is a transmissible cancer spread by biting during mating season. The original tumor cells derived from Schwann cells (cells that normally insulate nerves) in a single long-dead devil, and the cancer has since killed the majority of the Tasmanian devil population, pushing the species toward extinction.8PubMed Central. A Devil of a Transmissible Cancer Researchers have explicitly described it as “an infectious parasitic cell line.”9PubMed. Biting injuries and transmission of Tasmanian devil facial tumour disease Making matters worse, a second independent transmissible cancer, DFT2, was identified in Tasmanian devils in 2014, arising from a completely different cell lineage with a different chromosomal profile. That two separate transmissible cancers emerged in the same species suggests this phenomenon may be more common in nature than anyone assumed.10PubMed Central. A second transmissible cancer in Tasmanian devils
The marine world has its own version. Soft-shell clams along the Atlantic coast develop a form of leukemia caused by a single clonal cancer cell that spreads horizontally between animals in the water. Every tumor tested was genetically nearly identical and unrelated to its host clam, confirming that the cancer cells move between individuals as a contagious agent.11PubMed Central. Horizontal transmission of clonal cancer cells causes leukemia in soft-shell clams These cancers have their own genomes, their own evolutionary trajectories, and they survive by exploiting host after host. The semantic debate over whether cancer can be a parasite dissolves in these cases: the cancer literally is one.
Cancer as an Evolutionary Reversion
A separate line of thinking approaches the cancer-as-parasite question from an evolutionary angle. The atavistic model of cancer proposes that when cells become malignant, they are not inventing new capabilities from scratch. Instead, they are reverting to ancient genetic programs that predate the evolution of multicellular cooperation. Cancer, in this view, is a cell switching off the “teamwork” genes that evolved with complex animal bodies and switching on older survival programs that favor individual cell reproduction, much the way a single-celled organism behaves.12PubMed Central. Cancer progression as a sequence of atavistic reversions Support for this idea has come from genomic analyses showing that the genes most active in aggressive cancers tend to be evolutionarily older, while the genes that get shut down tend to be more recently evolved.13PubMed Central. Is Cancer Metabolism an Atavism?
A related but more provocative theory goes further, proposing that carcinogenesis is a form of speciation. In this framework, the chromosome-level chaos that occurs in cancer cells (gains and losses of whole chromosomes, massive rearrangements) is not simply “damage” but a process analogous to the chromosomal changes that give rise to new species. Over long latencies, these rearrangements occasionally produce a karyotype that is stable enough to be immortal and autonomous, essentially a new organism that survives by selection pressures similar to those that shape conventional species.14PubMed Central. Speciation Theory of Carcinogenesis Explains Karyotypic Individuality and Long Latencies of Cancers If taken seriously, this means cancers are not just parasitic in behavior; they are nascent organisms undergoing their own evolution. The branching, diversifying subclonal populations within a single tumor, documented extensively by genome sequencing, are subject to Darwinian selection in the same way populations of any organism are.15PubMed Central. Cancer evolution: Darwin and beyond
This is where the framing gets genuinely unsettling. A conventional tumor does not jump between hosts. But within a single host, it diversifies genetically, competes for resources, evades the host’s defenses, and evolves resistance to threats (including drugs). It has the internal evolutionary dynamics of a parasitic species even if it lacks the ability to transmit between hosts. The transmissible cancers discussed above show what happens when that last barrier falls away.
When a Parasite’s Own Cells Become Cancerous Inside a Human
If the conceptual boundary between cancer and parasite already feels thin, one extraordinary clinical case essentially erased it. In 2015, clinicians in Colombia found unusual clusters of small, undifferentiated cells in the lymph nodes and lungs of an HIV-positive man. The cells behaved like cancer: they were invasive, they multiplied, and they formed tumor-like masses. But they were abnormally small for human cells, and DNA testing revealed they were not human at all. They belonged to Hymenolepis nana, a dwarf tapeworm that had been living in the patient’s gut.16PubMed. Malignant Transformation of Hymenolepis nana in a Human Host
The tapeworm’s own cells had undergone malignant transformation, acquiring genetic mutations comparable to those seen in cancer, and then invaded the patient’s tissues as growing tumor masses. A parasite’s cells had become cancerous and were parasitizing the human host as tumors. The patient’s severely weakened immune system (due to HIV) likely allowed the abnormal tapeworm cells to grow unchecked. This case remains the only documented example of a parasite developing cancer that then invades a human, but it demonstrates how fluid the boundary between “parasite” and “cancer” can become under the right conditions.
Parasites That Cause Cancer Directly
There is also a well-established, less exotic connection between parasites and cancer. Several parasitic infections are recognized by the International Agency for Research on Cancer as definite causes of cancer in humans. Two species of liver fluke, Opisthorchis viverrini and Clonorchis sinensis, cause bile duct cancer (cholangiocarcinoma). The blood fluke Schistosoma haematobium causes bladder cancer. These parasites do not become tumors themselves; instead, the chronic inflammation, tissue damage, and cellular turnover their infections produce create conditions in which the host’s own cells are more likely to undergo malignant transformation. Malaria, while not classified as carcinogenic on its own, appears to act as a co-factor alongside Epstein-Barr virus in the development of Burkitt lymphoma in regions where both are common.17PubMed Central. Parasite Infection, Carcinogenesis and Human Malignancy
These parasites do not behave like cancer; they cause it. But the relationship adds another layer to the entanglement between parasitism and malignancy. The immune evasion tricks that cancer and helminths share may not be coincidental: if chronic parasite infection creates an environment that promotes cancer, and if cancer then uses the same immune-suppressing strategies as the parasite that helped spawn it, the two phenomena exist on a continuum rather than in separate categories.
What the Parasite Framework Means for Treatment
Viewing cancer through a parasitological lens is not just an intellectual exercise. It has practical therapeutic implications. One striking example is adaptive therapy, a treatment strategy that borrows directly from ecology. Instead of trying to kill every last cancer cell with maximum-dose chemotherapy, adaptive therapy deliberately allows some drug-sensitive cancer cells to survive. Those sensitive cells then compete with drug-resistant cells for resources, suppressing the resistant population the way a dominant species suppresses a competitor in an ecosystem.18PubMed Central. Towards Multidrug Adaptive Therapy The goal shifts from eradication to containment: maintaining a stable tumor burden rather than driving aggressive selection for resistance. This is parasite management logic applied to oncology.
Checkpoint immunotherapy also fits the framework. If cancer cells suppress the immune system using the same molecular switches that parasitic worms use, then drugs that block those switches (anti-PD-1 and anti-PD-L1 antibodies, for instance) are essentially reversing a parasitic immune evasion strategy. The clinical success of these drugs validates the idea that understanding cancer’s parasitic behavior leads to better interventions, not just better analogies.
Plant Tumors and the Wider Biology of Parasitic Growth
The parallels between parasitism and tumor growth are not limited to animals. Early in the twentieth century, the plant pathologist Erwin Smith drew detailed comparisons between plant galls caused by Agrobacterium tumefaciens (then called Phytobacterium tumefaciens) and animal cancers. He identified plant tumors resembling sarcomas, carcinomas, and teratomas, and noted that secondary tumors sometimes formed at sites far from the original infection, mirroring the metastasis seen in animal cancer.19Nature. Plant Tumours and Animal Cancer Smith’s view that animal cancer might have a bacterial origin did not hold up, but Agrobacterium really does cause uncontrolled cell growth in plants by inserting a segment of its own DNA into the plant cell’s genome. It is a genuine example of a parasite causing tumor-like growth by genetically reprogramming host cells, and the molecular tools derived from Agrobacterium are still used in genetic engineering today.
The plant case is useful because it shows that parasitic organisms commandeering host cell growth is a strategy that has evolved independently across kingdoms of life. The machinery of uncontrolled growth is not unique to animal cancer. Any time a parasitic relationship involves reprogramming host cells, the result can look and behave like a tumor, whether the host is a human, a dog, a clam, or a soybean plant.
Where the Analogy Breaks Down
For all its usefulness, the cancer-as-parasite framework has real limits. A conventional human tumor cannot transmit to another person. It does not have a life cycle with defined stages, intermediate hosts, or reproductive strategies aimed at reaching a new host. It does not form a genetically stable species in the way that even a simple parasitic worm does. A tumor’s “genome” is a moving target, with different subclones within a single mass carrying different mutations and competing with one another.20Cell. Intratumor Heterogeneity: Evolution through the Looking Glass A tapeworm, by contrast, has a stable genome, a reproductive system, and an evolutionary history shared with millions of other tapeworms. Cancer’s genetic individuality is one of its defining features: no two patients’ tumors are genetically alike, and even within a single tumor, diversity is the rule.
There is also a question of intent that matters ecologically, even if “intent” is too strong a word for organisms without consciousness. Successful parasites typically evolve toward an equilibrium with their host. A parasite that kills its host too quickly loses its home and its means of transmission. Many parasites moderate their virulence over evolutionary time. Cancer has no such pressure unless it happens to become transmissible. A conventional tumor’s evolutionary “interests” end with the host’s death, so there is no selection pressure toward coexistence. This makes cancer a uniquely destructive form of parasitism if you choose to call it that: one with no long-term strategy, no transmission bottleneck to impose moderation, and no evolutionary future beyond the individual host.